1. S14 Duration of Response After Ozanimod Withdrawal: Phase 3 True North Study Results. (December 2022) Authors: Sands, Bruce; Abraham, Bincy; Bressler, Brian; Reinisch, Walter; Jain, Anjali; Memaj, Arteid; Akukwe, Lucy; Jerry Liu, W.; Osterman, Mark; Canavan, James; Vermeire, Séverine Journal: American journal of gastroenterology Issue: Volume 117(2022)Supplement 2022 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S15 Efficacy of Ozanimod in Patients With Ulcerative Colitis Who Were Previously Exposed to Vedolizumab: True North Post Hoc Analysis. (December 2022) Authors: Sands, Bruce; Jain, Anjali; Harris, Ahmad; Osterman, Mark; Memaj, Arteid; Canavan, James; Axelrad, Jordan Journal: American journal of gastroenterology Issue: Volume 117(2022)Supplement 2022 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S723 Duration of Response to Ozanimod After Treatment Withdrawal: Results From the Phase 3 True North Study. (October 2022) Authors: Abraham, Bincy; Bressler, Brian; Reinisch, Walter; Jain, Anjali; Memaj, Arteid; Akukwe, Lucy; Liu, W. Jerry; Osterman, Mark; Canavan, James B.; Vermeire, Séverine Other Names: Sands Bruce E. presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10S Page Start: e506 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S731 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study. (October 2022) Authors: Dignass, Axel; Fischer, Monika; Sninsky, Charles; Armuzzi, Alessandro; Wu, Chun; Ahmad, Harris A.; Memaj, Arteid; Harris, Sarah; Canavan, James B.; Schreiber, Stefan Other Names: Afzali Anita presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10S Page Start: e513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S732 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Moderate orSevere Endoscopic Disease Activity at Baseline: A Post Hoc Analysis of the Phase 3 True North Study. (October 2022) Authors: Panaccione, Remo; Blumenstein, Irina; Long, Millie; Abraham, Bincy; Jain, Anjali; Memaj, Arteid; Wu, Chun; Hobbs, Vanessa; Harris, Sarah; Canavan, James B.; Peyrin-Biroulet, Laurent Other Names: Wolf Douglas C. presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10ES Page Start: e514 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S757 Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study. (October 2022) Authors: Dulai, Parambir; Dignass, Axel; Savarino, Edoardo; Hudesman, David; Afzali, Anita; Jairath, Vipul; Osterman, Mark; Akukwe, Lucy; Liu, W. Jerry; Memaj, Arteid; Petersen, AnnKatrin; Jain, Anjali; Canavan, James B.; Vermeire, Séverine Other Names: Abreu Maria T. presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10S Page Start: e537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S76 An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North Open-Label Extension Study. (December 2022) Authors: Abreu, Maria; Dulai, Parambir; Dignass, Axel; Savarino, Edoardo; Hudesman, David; Afzali, Anita; Jairath, Vipul; Osterman, Mark; Akukwe, Lucy; Jerry Liu, W.; Memaj, Arteid; Petersen, AnnKatrin; Jain, Anjali; Canavan, James; Vermeire, Séverine Journal: American journal of gastroenterology Issue: Volume 117(2022)Supplement 2022 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. S811 Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North Study. (October 2022) Authors: Irving, Peter; Blumenstein, Irina; Horst, Sara N.; Ahmad, Harris A.; Lawlor, Garrett; Hobbs, Vanessa; Jain, Anjali; Memaj, Arteid; Ananthakrishnan, Ashwin N. Other Names: Khan Nabeel presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10ES Page Start: e580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. S825 Efficacy of Ozanimod in Vedolizumab-Exposed Patients With Ulcerative Colitis: A Phase 3 True North Post Hoc Analysis. (October 2022) Authors: Jain, Anjali; Ahmad, Harris A.; Osterman, Mark; Memaj, Arteid; Canavan, James B.; Axelrad, Jordan Other Names: Sands Bruce E. presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10ES Page Start: e593 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. S98 Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: A Post Hoc Analysis From True North. (December 2022) Authors: Khan, Nabeel; Irving, Peter; Blumenstein, Irina; Horst, Sara; Ahmad, Harris; Lawlor, Garrett; Hobbs, Vanessa; Jain, Anjali; Memaj, Arteid; Ananthakrishnan, Ashwin Journal: American journal of gastroenterology Issue: Volume 117(2022)Supplement 2022 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗